Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA

20 Nov 2019 - ACN Newswire
SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological ...
lse:sle hkex:272

---

SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK

30 Oct 2019 - ACN Newswire
SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological ...
hkex:2611 hkex:665 lse:cmb hkex:6178 hkex:8001 lse:sle sgx:u9e hkex:1788

---